Literature DB >> 22388160

Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.

Philip Seeman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22388160     DOI： 10.1097/JCP.0b013e318248daaa

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  4 in total

1.  Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012).

Authors:  Philip Seeman
Journal:  Psychopharmacology (Berl)       Date:  2012-03-13       Impact factor: 4.530

Review 2.  Is schizophrenia a dopamine supersensitivity psychotic reaction?

Authors:  Mary V Seeman; Philip Seeman
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-12       Impact factor: 5.067

Review 3.  Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.

Authors:  Michael W Huang; Roger Carl Gibson; Mahesh B Jayaram; Stanley N Caroff
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 4.  Clozapine, a fast-off-D2 antipsychotic.

Authors:  Philip Seeman
Journal:  ACS Chem Neurosci       Date:  2013-11-18       Impact factor: 4.418
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.